Navigation Links
ViThera Novel Approach Using Probiotics to Deliver Elafin Shows Promise as a Future Inflammatory Bowel Disease (IBD) Treatment
Date:10/31/2012

CAMBRIDGE, Mass., Oct. 31, 2012 /PRNewswire/ -- ViThera Pharmaceuticals, Inc, a developer of novel therapeutics based on engineered probiotic bacteria, announced today the publication of breakthrough data validating its approach for the delivery of elafin in treating gastrointestinal inflammation. The results were published today by the journal Science Translational Medicine and show use of recombinant probiotic and non-pathogenic food-strain bacteria to deliver elafin, a protein designed to protect human mucosal tissue during inflammation. The publication by senior author Nathalie Vergnolle and ViThera co-founder Philippe Langella describes a series of preclinical experiments successfully validating elafin as a novel treatment approach with future applications for human inflammatory bowel disease (IBD).

ViThera's President, Johannes Fruehauf, commented, "We are excited about the recognition that this publication entails and we congratulate Nathalie and Philippe on this important achievement." ViThera has obtained worldwide exclusive rights to the technology and is developing it further towards validation in clinical trials in close collaboration with Dr. Vergnolle and Dr. Langella. ViThera's VT301 program, currently in preclinical development, focuses on restoring and maintaining the integrity of the gut epithelium in patients with IBD by delivering elafin. This treatment is designed to help patients with active disease achieve remission faster and patients in remission to avoid flare-ups. VT301 is expected to enter clinical trials in two years for patients with mild to moderate ulcerative colitis.

About ViThera Pharmaceuticals

ViThera is a startup biotechnology company based in Cambridge, Massachusetts. Its research combines innovative molecular biology with the benefits of probiotics to create therapeutics for a variety of chronic diseases, including inflammatory bowel diseases like Crohn's disease and ulcerative colitis. ViThera is using its EnLact™ platform, combining synthetic biology in engineered probiotic bacteria to deliver therapeutic molecules in the gastrointestinal (GI) tract. ViThera is privately owned. www.vitherapharma.com


'/>"/>
SOURCE ViThera Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
2. S*BIOs Novel JAK2 Inhibitor Pacritinib (SB1518) and Histone Deacetylase Inhibitor Pracinostat (SB939) Demonstrate Promising Activity in Phase 2 Studies for Patients with Myelofibrosis (MF)
3. New magnetic-field-sensitive alloy could find use in novel micromechanical devices
4. Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech
5. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
6. Arcion Receives Notice of Allowance for US Patent for Novel Topical Lidocaine Formulation for Pain
7. Nabsys Expands Leadership Team to Prepare for Commercialization of Novel DNA Positional Sequencing Technology
8. Boulder Diagnostics Licenses Novel Rapid Detection Technology for Homocysteine and Related Compounds from Portland State University
9. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
10. Lupus Research Institute Awards $3.6 Million for Novel Studies Driving Wide-Ranging New Science in Lupus
11. Novel method to make nanomaterials discovered
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network for ... Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is to ... are designed, built and brought to market. , The Design Lab is Supplyframe’s ...
(Date:6/23/2016)... June 23, 2016 ... 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published recently ... peer-reviewed journal from touchONCOLOGY, Andrew D Zelenetz ... of cancer care is placing an increasing burden ... expensive biologic therapies. With the patents on many ...
Breaking Biology Technology:
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... for financial services, but it also plays a fundamental part ...
(Date:4/19/2016)... April 20, 2016 The new ... a compact web-based "all-in-one" system solution for all door ... reader or the door interface with integration authorization management ... control systems. The minimal dimensions of the access control ... the building installations offer considerable freedom of design with ...
Breaking Biology News(10 mins):